Authors
Latest:
Clinically Meaningful Outcome Measures: A Role for Geriatric AssessmentNora Kovar, MD, MPH; and Melissa L. Teply, MD, give their perspective on research from Quirin Zangl, MD, published in ONCOLOGY regarding geriatric assessment in patients with genitourinary carcinoma.
Latest:
Oncology Peer Review On-The-Go: Improving Testing Access and Guiding Treatment Options with TrialJectoryThe latest podcast episode of Oncology Peer Review On-The-Go features a conversation with Tzvia Bader and Karine Perreault on TrialJectory’s platform, which seeks to guide patients with cancer on their treatment journey.
Latest:
Expert Commentary On The Product Profile Of DostarlimabIn an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of dostarlimab as therapy for adult patients with recurrent or advanced solid tumors with deficient mismatch repair.
Latest:
Key Takeaways on the Treatment of Patients With Relapsed/Refractory MMThe expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.
Latest:
Key Takeaways from Health Care Systems on the Role of Bispecifics in MMThe panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.
Latest:
Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCCToni Choueiri, MD, and Rohit Gosain, MD summarize the implications of the CheckMate 9ER 3-year follow-up data and highlight remaining questions and unmet needs in the RCC landscape.
Latest:
Biagio Ricciuti, MD, Looks Toward Future Research in NSCLC Involving PD-L1 ExpressionBiagio Ricciuti, MD, spoke about future analyses and major takeaways of a study analyzing outcomes with frontline immunotherapy based on PD-L1 expression in patients with non–small cell lung cancer.
Latest:
Key Takeaways & Clinical ImplicationsA commentary on key takeaways from TROPiCS-02, remaining questions and unmet needs in the field, and the clinical implications of using SG and other Trop-2–directed ADCs in patients with HR+/HER2- mBC.
Latest:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsThe aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
Latest:
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell TumorIn this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.
Latest:
Key Takeaways on Evolving Treatment Landscape in Multiple MyelomaThe expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
Latest:
Unmet Needs and Future Perspectives in NSCLC TreatmentThe panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.
Latest:
Recap: Bladder Cancer Treatment AlgorithmThe Oncology Brothers recap the discussion on treatment practices for patients with bladder cancer.
Latest:
Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy ResponseCancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.
Latest:
Metastatic Renal Cell Carcinoma With Sarcomatoid FeaturesIn this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.
Latest:
Knowledge, Understanding are Key to Mitigating RCC Treatment DisparitiesIt is important not to wash over the disparities in treatment access for renal cell carcinoma as merely another statistic and take action on guiding patients to treatment, says Solomon Woldu, MD.
Latest:
Unmet Needs and Future Perspectives in Multiple MyelomaA panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.
Latest:
Standard HER2 Assays Do Not Accurately Identify HER2-Low Breast CancerData collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.
Latest:
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research RecommendationsThis review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Latest:
The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral CenterCOVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Latest:
Future Directions in Graft vs Host Disease ManagementClosing out their panel on GVHD management, expert hematologist/oncologists share their hope for future evolution in the treatment landscape.
Latest:
ctDNA Assay May Elucidate Outcomes With Chemo in HR+ Breast CancerFuture research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Latest:
Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular LymphomaExpert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.
